SAB Biotherapeutics (SABS) vs Scribe Therapeutics (SCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
SAB Biotherapeutics is the larger company by market cap ($253.1 million vs $228.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SABS | SCTX |
|---|---|---|
| Share price | $2.81 | $12.07 |
| Market cap | $253.15M | $228.58M |
| 1-day change | -3.44% | -8.70% |
| YTD return | -24.87% | — |
| 1-year return | -28.86% | — |
| 5-year return | -97.32% | — |
| EPS (TTM) | $-1.35 | $-6.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $13.27M | — |
| 52-week high | $5.15 | $39.60 |
| 52-week low | $2.44 | $12.00 |
| Distance from 52-week high | -45.44% | -69.52% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +314.23% | +372.25% |
| Average volume | 633.60K | 403.27K |
| Shares outstanding | 90.09M | 18.94M |
| Employees | 86 | 77 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About SAB Biotherapeutics
SABS stock →SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 86 employees
About Scribe Therapeutics
SCTX stock →Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 77 employees
SABS vs SCTX FAQ
Which is bigger, SAB Biotherapeutics or Scribe Therapeutics?
SAB Biotherapeutics (SABS) is larger, with a market capitalization of $253.15M compared with $228.58M for Scribe Therapeutics (SCTX).
Are SAB Biotherapeutics and Scribe Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.